Skip to main content

Advertisement

SpringerLink
Log in

Immunopathogenesis of acute graft-versus-host disease: implications for novel preventive and therapeutic strategies

  • Review Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Acute graft-versus-host disease (GVHD) is a primary T-cell-mediated complication of allogeneic hematopoietic stem cell transplantation (HSCT), occurring when donor-derived T cells are stimulated by host antigen-presenting cells (APCs), enhanced by proinflammatory cytokines such as interleukin (IL)-1, IL-6, IL-8, and tumor necrosis factor (TNF)-alpha. Recent data indicate that besides differences in major histocompatibility and minor histocompatibility antigens, cytokine gene polymorphisms have a predictive value for the complication of GVHD. Patients with a high anti-inflammatory IL-10 production have been demonstrated to be protected from GVHD while patients with high TNF-alpha serum levels were more at risk for GVHD. Pharmacological immunosuppression for GVHD prophylaxis and therapy, including unspecific approaches with corticosteroids or methotrexate (MTX), as well as more specific therapy with cyclosporin A (CsA), tacrolimus (FK506), sirolimus, mycophenolate mofetil (MMF), antithymocyte globulin (ATG), and monoclonal antibodies (MAbs) directed against CD3, CD25, CD52, cytotoxic T-lymphocyte antigen (CTLA)-4, CD40 ligand, or TNF-alpha, have been proven to be effective. Recent data on novel techniques to selectively deplete alloreactive T cells by removal, destruction, or anergy induction while preserving leukemia-specific T-cell clones suggest a clinical benefit from these approaches. Gene-modified T cells that can selectively be depleted and CD4+CD25+ regulatory T cells are under investigation for their ability to modulate alloreactivity after HSCT. With a better understanding of the immunopathogenesis of acute GVHD and the technical improvement of recently described therapeutic approaches, such as removal of naive T cells, selection of Th2 cells, suicide gene transduced T cells, and adoptive transfer of regulatory T cells, the use of alloreactivity as a treatment modality may be expanded to nonhematological disease entities such as solid tumors or autoimmune disorders.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Appelbaum FR (2001) Haematopoietic cell transplantation as immunotherapy. Nature 411:385–389

    CAS  PubMed  Google Scholar 

  2. Ho VT, Soiffer RJ (2001) The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood 98:3192–3204

    Article  CAS  PubMed  Google Scholar 

  3. Shlomchik WD, Couzens MS, Tang CB, McNiff J, Robert ME, Liu J, Shlomchik MJ, Emerson SG (1999) Prevention of graft-versus-host disease by inactivation of host antigen-presenting cells. Science 285:412–415

    Article  CAS  PubMed  Google Scholar 

  4. Ferrara JL, Cooke KR, Teshima T (2003) The pathophysiology of acute graft-versus-host disease. Int J Hematol 78:181–187

    CAS  PubMed  Google Scholar 

  5. Mowat AM, Felstein MV (1990) Experimental studies of immunologically mediated enteropathy. V. Destructive enteropathy during an acute graft-versus-host reaction in adult BDF1 mice. Clin Exp Immunol 79:279–284

    CAS  PubMed  Google Scholar 

  6. Teshima T, Ordemann R, Reddy P, Gagin S, Liu C, Cooke KR, Ferrara JL (2002) Acute graft versus host disease does not require alloantigen expression on host epithelium. Nat Med 8:575–581

    Article  CAS  PubMed  Google Scholar 

  7. Halverson DC, Schwartz GN, Carter C, Gress RE, Powler DH (1997) In vitro generation of allospecific human CD8+ T cells of Tc1 and Tc2 phenotype. Blood 90:2089–2096

    CAS  PubMed  Google Scholar 

  8. Shustov A, Nguyen P, Finkelman F, Elkeon KB, Via CS (1998) Differential expression of Fas and Fas ligand in acute and chronic graft-versus-host disease: up-regulation of Fas and Fas ligand requires CD8+ T cell activation and IFN-production. J Immunol 161:2848–2855

    CAS  PubMed  Google Scholar 

  9. Lin T, Brunner T, Tietz B, Madsen J, Bonfoco E, Reaves M, Huflejt M, Green DR (1998) Fas ligand-mediated killing by intestinal intraepithelial lymphocytes. J Clin Invest 101:570–577

    CAS  PubMed  Google Scholar 

  10. Murai M, Yoneyama H, Harada A, Yi Z, Vestergaard C, Guo B, Suzuki K, Asakura H, Matsushima K (1999) Active participation of CCR5+CD8+ T lymphocytes in the pathogenesis of liver injury in graft-versus-host disease. J Clin Invest 104:49–57

    CAS  PubMed  Google Scholar 

  11. Murai M, Yoneyama H, Ezaki T, Suematsu M, Terashima Y, Harada A, Hamada H, Asakura H, Ishikawa H, Matsushima K (2003) Peyer’s patch is the essential site in initiating murine acute and lethal graft-versus-host reaction. Nat Immunol 4:154–160

    Article  CAS  PubMed  Google Scholar 

  12. Kunkel EJ, Butcher EC (2002) Chemokines and the tissue-specific migration of lymphocytes. Immunity 16:1–4

    PubMed  Google Scholar 

  13. Campbell DJ, Butcher EC (2002) Rapid acquisition of tissue-specific homing phenotypes by CD4+ T cells activated in cutaneous or mucosal lymphoid tissues. J Exp Med 195:135–141

    Article  CAS  PubMed  Google Scholar 

  14. FerraraJL, Deeg HJ (1991) Graft-versus-host disease. N Engl J Med 324:667–674

    Google Scholar 

  15. Trinchieri G (1989) Biology of natural killer cells. Adv Immunol 47:187–376

    CAS  PubMed  Google Scholar 

  16. Marsh SG, Parham P, Dupont B, Geraghty DE, Trowsdale J, Middleton D, Vilches C, Carrington M, Witt C, Guethlein LA, Shilling H, Garcia CA, Hsu KC, Wain H (2003) Killer cell immunoglobulin receptor (KIR) Nomenclature Report 2002. Hum Immunol 64:648–654

    CAS  PubMed  Google Scholar 

  17. Vilches C, Parham P (2002) KIR: diverse rapidly evolving receptors of innate and adoptive immunity. Annu Rev Immunol 20:217–251

    CAS  PubMed  Google Scholar 

  18. Kärre K (2002) Clever, cleverer, cleverest. Nat Immunol 3:505–506

    PubMed  Google Scholar 

  19. Ljunggren HG, Karre K (1990) In search of the ‘missing self’: MHC molecules and NK cell recognition. Immunol Today 11:237–244

    CAS  PubMed  Google Scholar 

  20. Ruggeri L, Campanni M, Martelli MF, Velardi A (2001) Cellular therapy: exploiting NK cell alloreactivity in transplantation. Curr Opin Hematol 8:355–359

    Article  CAS  PubMed  Google Scholar 

  21. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli MF, Velardi A (2002) Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295:2097–2100

    Article  CAS  PubMed  Google Scholar 

  22. Giebel S, Locatelli F, Lamparelli T, Velardi A, Davies S, Frumento G, Maccario R, Bonetti F, Wojnar J, Martinetti M, Frassoni F, Giorgiani G, Bacigalupo A, Holowiecki J (2003) Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 102:814–819

    Article  CAS  PubMed  Google Scholar 

  23. Davies SM, Ruggieri L, DeFor T, Wagner JE, Weisdorf DJ, Miller JS, Velardi A, Blazar BR (2002) Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood 100:3825–3827

    Article  CAS  PubMed  Google Scholar 

  24. Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringden O (2003) Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 57:11–20

    Article  PubMed  Google Scholar 

  25. Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC (2003) Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 75:389–397

    Article  CAS  PubMed  Google Scholar 

  26. Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, Grisanti S, Gianni AM (2002) Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99:3838–3843

    Article  PubMed  Google Scholar 

  27. Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, Hardy W, Devine S, Ucker D, Deans R, Moseley A, Hoffman R (2002) Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 72:1653–1655

    Google Scholar 

  28. Lange A, Klimczak A, Karabon L, Suchniki K (1991) Cytokines, adhesion molecules (E-selectin and VCAM-1) and acute graft-versus-host disease. Arch Immunol Ther Exp 43:99–105

    Google Scholar 

  29. Richard S, Seigneur M, Blann A, Adams R, Renard M, Puntous M, Boiron JM, Amiral J, Reiffers J, Boisseau M (1996) Vascular endothelial lesion in patients undergoing bone marrow transplantation. Bone Marrow Transplant 18:955–959

    CAS  PubMed  Google Scholar 

  30. Tanaka J, Imamura M, Kasai M, Hashino S, Kobayashi S, Noto S, Higa T, Sakurada K, Asaka M (1997) The important balance between cytokines derived from type 1 and type 2 helper T cells in the control of graft-versus-host disease. Bone Marrow Transplant 19:571–576

    Article  CAS  PubMed  Google Scholar 

  31. Krenger W, Ferrara JL (1996) Dysregulation of cytokines during graft-versus-host disease. J Hematother 5:3–14

    CAS  PubMed  Google Scholar 

  32. Lin MT, Storer B, Martin PJ, Tseng LH, Gooley T, Chen PJ, Hansen JA (2003) Relation of an interleukin-10 promotor polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. N Engl J Med 349:2201–2210

    Article  CAS  PubMed  Google Scholar 

  33. Holler E, Kolb HJ, Moller A, Kempeni J, Liesenfeld S, Pechumer H, Lehmacher W, Ruckdeschel G, Gleixner B, Riedner C, et al. (1990) Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood 75:1011–1016

    CAS  PubMed  Google Scholar 

  34. Loetscher P, Uguccioni M, Bordoli L, Baggiolini M, Moser B, Chizzolini C, Dayer JM (1998) CCR5 is characteristic of Th1 lymphocytes. Nature 391:344–345

    CAS  PubMed  Google Scholar 

  35. Qin S, Rottman JB, Myers P, Kassam N, Weinblatt M, Loetscher M, Koch AE, Moser B, Mackay CR (1998) The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest 101:746–754

    CAS  PubMed  Google Scholar 

  36. Zhou Y, Kurihara T, Ryseck RP, Yang Y, Ryan C, Loy J, Warr G, Bravo R (1998) Impaired macrophage function and enhanced T cell-dependent immune response in mice lacking CCR5, the mouse homologue of the major HIV-1 coreceptor. J Immunol 160:4018–4025

    CAS  PubMed  Google Scholar 

  37. Taub DD, Conlon K, Lloyd AR, Oppenheim JJ, Kelvin D (1993) Preferential migration of activated CD4+ and CD8+ T cells in response to MIP-1 alpha and MIP-1 beta. Science 260:355–358

    CAS  PubMed  Google Scholar 

  38. Schall TJ, Bacon K, Camp RD, Kaspari JW, Goeddel DV (1993) Human macrophage inflammatory protein alpha (MIP-1 alpha) and MIP-1 beta chemokines attract distinct populations of lymphocytes. J Exp Med 177:1821–1826

    CAS  PubMed  Google Scholar 

  39. Serody JS, Cook DN, Kirby SL, Reap E, Shea TC, Frelinger JA (1999) Murine T lymphocytes incapable of producing macrophage inhibitory protein-1 are impaired in causing graft-versus-host disease across a class I but not class II major histocompatibility complex barrier. Blood 93:43–50

    CAS  PubMed  Google Scholar 

  40. Serody JS, Burkett SE, Panoskaltsis-Mortari A, Ng-Cashin J, McMahon E, Matsushima GK, Lira SA, Cook DN, Blazar BR (2000) T-lymphocyte production of macrophage inhibitory protein-1 is critical to the recruitment of CD8+ T cells to the liver, lung and spleen during graft-versus-host disease. Blood 96:2973–2980

    CAS  PubMed  Google Scholar 

  41. Panoskaltsis-Mortari A, Hermanson JR, Taras E, Wangensteen OD, Serody JS, Blazar BR (2003) Acceleration of idiopathic pneumonia syndrome (IPS) in the absence of donor MIP-1 alpha (CCL3) after allogeneic BMT in mice. Blood 101:3714–3721

    Article  CAS  PubMed  Google Scholar 

  42. Beatty PG, Clift RA, Mickelson EM, Nisperos BB, Flournoy N, Martin PJ, Sanders JE, Stewart P, Buckner CD, Storb R, et al. (1985) Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 313:765–771

    CAS  PubMed  Google Scholar 

  43. Drobyski WR, Klein J, Flomenberg N, Pietryga D, Vesole DH, Margolis DA, Keever-Taylor CA (2002) Superior survival associated with transplantation of matched unrelated versus one-antigen-mismatched unrelated or highly human leukocyte antigen-disparate haploidentical family donor marrow grafts for the treatment of hematologic malignancies: establishing a treatment algorithm for recipients of alternative donor grafts. Blood 99:806–814

    Article  CAS  PubMed  Google Scholar 

  44. Szydlo R, Goldman JM, Klein JP, Gale RP, Ash RC, Bach FH, Bradley BA, Casper JT, Flomenberg N, Gajewski JL, et al. (1997) Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol 5:1767–1777

    Google Scholar 

  45. Speiser DE, Tiercy JM, Rufer N, Grundschober C, Gratwohl A, Chapuis B, Helg C, Loliger CC, Siren MK, Roosnek E, et al. (1996) High resolution HLA matching associated with decreased mortality after unrelated bone marrow transplantation. Blood 87:4455–4462

    CAS  PubMed  Google Scholar 

  46. Sasazuki T, Juji T, Morishima Y, Kinukawa N, Kashiwabara H, Inoko H, Yoshida T, Kimura A, Akaza T, Kamikawaji N, Kodera Y, et al. (1998) Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. Japan Marrow Donor Program. N Engl J Med 339:1177–1185

    Article  CAS  PubMed  Google Scholar 

  47. Prasad VK, Kernan NA, Heller G, O’Reilly RJ, Yang SY (1999) DNA typing for HLA-A and HLA-B identifies disparities between patients and unrelated donors matched by HLA-A and HLA-B serology and HLA-DRB1. Blood 93:399–409

    CAS  Google Scholar 

  48. Perreault C, Roy DC, Fortin C (1998) Immunodominant minor histocompatibility antigens: the major ones. Immunol Today 19:69–74

    CAS  PubMed  Google Scholar 

  49. de Bueger M, Bakker A, van Rood JJ, van der Woude F, Goulmy E (1992) Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicated heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens. J Immunol 149:1788–1794

    PubMed  Google Scholar 

  50. Dickinson AM, Sviland L, Carey P, Reid MM, Hamilton PJ, Pearson AJ, Proctor SJ (1988) Skin explant culture as a model for cutaneous graft-versus-host disease in humans. Bone Marrow Transplant 3:323–329

    CAS  PubMed  Google Scholar 

  51. Dickinson AM, Wang XN, Sviland L, Vyth-Dreese FA, Jackson GH, Schumacher TN, Haanen JB, Mutis T, Goulmy E (2002) In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens. Nat Med 8:410–414

    Article  CAS  PubMed  Google Scholar 

  52. Hattori K, Hirano T, Miyajima H, Yamakawa N, Tateno M, Oshimi K, Kayagaki N, Yagita H, Okumura K (1998) Differential effects of anti-Fas ligand and anti-tumor necrosis factor alpha antibodies on acute graft-versus-host disease pathologies. Blood 91:4051–4055

    CAS  PubMed  Google Scholar 

  53. Grainger DJ, Heathcote K, Chiano M, Snieder H, Kemp PR, Metcalfe JC, Carter ND, Spector TD (1999) Genetic control of the circulating concentration of transforming growth factor type beta 1. Hum Mol Genet 8:93–97

    CAS  PubMed  Google Scholar 

  54. Bidwell JL, Wood NA, Morse HR, Olomolaiye OO, Laundy GJ (1998) Human cytokine gene nucleotide sequence alignments. Eur J Immunogenet 25:83–265

    CAS  PubMed  Google Scholar 

  55. Bidwell JL, Wood NA, Morse HR, Olomolaiye OO, Keen JL, Laundy GJ (1999) Human cytokine gene nucleotide sequence alignments: supplement 1. Eur J Immunogenet 26:135–223

    Article  CAS  PubMed  Google Scholar 

  56. Turner D, Grant SC, Yonan N, Sheldon S, Dyer PA, Sinnott PJ, Hutchinson IV (1997) Cytokine gene polymorphism and heart transplant rejection. Transplantation 64:776–779

    CAS  PubMed  Google Scholar 

  57. Middleton PG, Taylor PRA, Jackson GH, Proctor SJ, Dickinson AM (1998) Cytokine gene polymorphisms association with severe graft-versus-host disease in HLA-identical sibling transplants. Blood 92:3943–3948

    CAS  PubMed  Google Scholar 

  58. Middleton PG, Cullup H, Dickinson AM, Norden J, Jackson GH, Taylor PR, Cavet J (2002) Vitamin D receptor gene polymorphism associates with graft-versus-host disease and survival in HLA-matched sibling allogeneic bone marrow transplantation. Bone Marrow Transplant 30:223–228

    Article  CAS  PubMed  Google Scholar 

  59. Middleton PG, Cullup H, Cavet J, Jackson GH, Taylor PRA, Dickinson AM (2003) Estrogen receptor alpha gene polymorphism associates with occurrence of graft-versus-host disease and reduced survival in HLA-matched sib-allo BMT. Bone Marrow Transplant 32:41–47

    Article  CAS  PubMed  Google Scholar 

  60. Inohara N, Ogura Y, Nunez G (2002) Nods: a family of cytosolic proteins that regulate the host response to pathogens. Curr Opin Microbiol 5:76–80

    Article  CAS  PubMed  Google Scholar 

  61. Berrebi D, Maudinas R, Hugot JP, Chamaillard M, Chareyre F, De Lagausie P, Yang C, Desreumaux P, Giovannini M, Cezard JP, Zouali H, Emilie D, Peuchmaur M (2003) Card15 gene overexpression in mononuclear and epithelial cells of the inflamed Crohn’s disease colon. Gut 52:840–846

    Article  CAS  PubMed  Google Scholar 

  62. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, Almer S, Tysk C, O’Morain CA, Gassull M, Binder V, Finkel Y, Cortot A, Modigliani R, Laurent-Puig P, Gower-Rousseau C, Macry J, Colombel JF, Sahbatou M, Thomas G (2001) Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature 411:599–603

    PubMed  Google Scholar 

  63. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, Britton H, Moran T, Karaliuskas R, Duerr RH, Achkar JP, Brant SR, Bayless TM, Kirschner BS, Hanauer SB, Nunez G, Cho JH (2001) A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature 411:603–606

    PubMed  Google Scholar 

  64. Holler E, Rogler G, Herfarth H, Brenmoehl J, Wild PJ, Hahn J, Eissner G, Schoelmerich J, Andreesen R (2004) Both, donor and recipient NOD2/CARD15 mutations associate with transplant-related mortality and GvHD following allogeneic stem cell transplantation. Blood [Epub ahead of print]

  65. Cullup H, Jarvis M, Wang XN, Sviland L, Dickinson AM (2002) Expression of interleukin-1 alpha and interleukin-1 receptor antagonist associates with the severity of graft-versus host reaction in a human skin explant model. Hematol J 3 [Suppl 2]:136a

    Google Scholar 

  66. Korngold R, Sprent J (1999) Murine models for graft-versus-host disease. In: Thomas ED, Blume KG, Forman SJ (eds) Hematopoietic cell transplantation. Blackwell Science, Boston, pp 296–304

  67. van Bekkum DW, Roodenburg J, Heidt PJ, van der Waaij D (1974) Mitigation of secondary disease of allogeneic mouse radiation chimeras by modification of the intestinal microflora. J Natl Cancer Inst 52:401–404

    PubMed  Google Scholar 

  68. van Bekkum DW, Knaan S (1977) Role of bacterial microflora in development of intestinal lesions from graft-versus-host reaction. J Natl Cancer Inst 58:787–790

    PubMed  Google Scholar 

  69. Antin JH (2001) Acute graft-versus-host disease: inflammation run amok? J Clin Invest 107:1497–1498

    CAS  PubMed  Google Scholar 

  70. Cooke KR, Olkiewicz K, Erickson N, Ferrara JL (2002) The role of endotoxin and the innate immune response in the pathophysiology of acute graft versus host disease. J Endotoxin Res 8:441–448

    Article  CAS  PubMed  Google Scholar 

  71. Ferrara J (2003) Location, location, location. Nat Immunol 4:103–104

    Article  CAS  PubMed  Google Scholar 

  72. Hill GR, Ferrara JL (2000) The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 95:2754–2759

    CAS  PubMed  Google Scholar 

  73. Panoskaltsis-Mortari A, Lacey DL, Vallera DA, Blazer BR (1998) Keratinocyte growth factor administered before conditioning ameliorates graft-versus-host disease after allogeneic bone marrow transplantation in mice. Blood 92:3960–3967

    CAS  PubMed  Google Scholar 

  74. Bleyer WA (1977) Methotrexate: clinical pharmacology, current status and therapeutic guidelines. Cancer Treat Rev 4:87–92

    CAS  PubMed  Google Scholar 

  75. Storb R, Epstein RB, Graham TC, Thomas ED (1970) Methotrexate regimens for control of graft-versus-host disease in dogs with allogeneic marrow grafts. Transplantation 9:240–246

    CAS  PubMed  Google Scholar 

  76. Fabre G, Goldman ID (1985) Formation of 7-hydroxymethotrexate polyglutamyl derivatives and their cytotoxicity in human chronic myelogenous leukemia cells, in vitro. Cancer Res 45:80–85

    CAS  PubMed  Google Scholar 

  77. Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W, Buckner CD, Clift R, Doney K, Farewell V (1986) Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 314:729–734

    CAS  PubMed  Google Scholar 

  78. Antin JH, Ferrara JL (1992) Cytokine dysregulation and acute graft-versus-host disease. Blood 80:2964–2972

    CAS  PubMed  Google Scholar 

  79. Almawi WY, Lipman ML, Stevens AC, Zanker B, Hadro ET, Strom TB (1991) Abrogation of glucocorticoid-mediated inhibition of T cell proliferation by the synergistic action of IL-1, IL-6 and IFN gamma. J Immunol 146:3523–3529

    CAS  PubMed  Google Scholar 

  80. Holler E, Kolb HJ, Wilmanns W (1993) Treatment of GVHD–TNF-antibodies and related antagonists. Bone Marrow Transplant 12 [Suppl 3]:29

    PubMed  Google Scholar 

  81. Chao NJ, Schmidt GM, Niland JC, Amylon MD, Dagis AC, Long GD, Nademanee AP, Negrin RS, O’Donnell MR, Parker PM, Smith EP, Snyder DS, Stein AS, Wong RM, Blume KG, Forman SJ (1993) Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med 329:1225–1230

    Article  CAS  PubMed  Google Scholar 

  82. Chao NJ, Snyder DS, Jain M, Wong RM, Niland JC, Negrin RS, Long GD, Hu WW, Stockerl-Goldstein KE, Johnston LJ, Amylon MD, Tierney DK, O’Donnell MR, Nademanee AP, Parker P, Stein A, Molina A, Fung H, Kashyap A, Kohler S, Spielberger R, Krishnan A, Rodriguez R, Forman SJ, Blume KG (2000) Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: results of a prospective double-blind randomized trial. Biol Blood Marrow Transplant 6:254–261

    CAS  PubMed  Google Scholar 

  83. Ruutu T, Volin L, Parkkali T, Juvonen E, Elonen E (2000) Cyclosporine, methotrexate, and methylprednisolone compared with cyclosporine and methotrexate for the prevention of graft-versus-host disease in bone marrow transplantation from HLA-identical sibling donor: a prospective randomized study. Blood 96:2391–2398

    CAS  PubMed  Google Scholar 

  84. Borel JF (1993) The history of cyclosporin A and its significance. In: White DJG (ed) Cyclosporin A. Elsevier, New York, pp 5–11

  85. Kino T, Hatanaka H, Miyata S, Inamura N, Nishiyama M, Yajima T, Goto T, Okuhara M, Kohsaka M, Aoki H (1987) FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo) 40:1256–1265

    Google Scholar 

  86. Bram RJ, Hung DT, Martin PK, Schreiber SL, Crabtree GR (1993) Identification of the immunophilins capable of mediating inhibition of signal transduction by cyclosporin A and FK506: roles of calcineurin binding and cellular location. Mol Cell Biol 13:4760–4769

    CAS  PubMed  Google Scholar 

  87. Bennett WM, Pulliam JP (1983) Cyclosporine nephrotoxicity. Ann Intern Med 99:851–858

    CAS  PubMed  Google Scholar 

  88. Petric R, Freeman D, Wallace C, McDonald J, Stiller C, Keown P (1988) Effect of cyclosporine on urinary prostanoid excretion, renal blood flow, and glomerulotubular function. Transplantation 45:883–889

    CAS  PubMed  Google Scholar 

  89. Gluckman E, Lokeic F, Devergie A (1980) Pharmacokinetic monitoring of cyclosporine in allogeneic bone marrow transplants. Transplant Proc 20:122–129

    Google Scholar 

  90. Yee GC, Self SG, McGuire TR, Carlin J, Sanders JE, Deeg HJ (1988) Serum cyclosporine concentration and risk of acute graft-versus-host disease after allogeneic marrow transplantation. N Engl J Med 319:65–70

    CAS  PubMed  Google Scholar 

  91. Przepiorka D, Ippoliti C, Khouri I, Woo M, Mehra R, Le Bherz D, Giralt S, Gajewski J, Fischer H, Fritsche H, Deisseroth AB, Cleary K, Champlin R, Besien K, Andersson B, Maher R, Fitzsimmons W (1996) Tacrolimus and mini dose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation. Blood 88:4383–4389

    CAS  PubMed  Google Scholar 

  92. Fay JW, Wingard JR, Antin JH, Collins RH, Pineiro LA, Blazar BR, Saral R, Bierer BE, Przepiorka D, Fitzsimmons WE, Maher RM, Weisdorf DJ (1996) FK506 (Tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogeneic bone marrow transplantation. Blood 87:3514–3519

    CAS  PubMed  Google Scholar 

  93. Nash RA, Pineiro LA, Storb R, Deeg HJ, Fitzsimmons WE, Furlong T, Hansen JA, Gooley T, Maher RM, Martin P, McSweeney PA, Sullivan KM, Anasetti C, Fay JW (1996) Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study. Blood 88:3634–3641

    CAS  PubMed  Google Scholar 

  94. Nash RA, Antin JH, Karanes C, Fay JW, Avalos BR, Yeager AM, Przepiorka D, Davies S, Petersen FB, Bartels P, Buell D, Fitzsimmons W, Anasetti C, Storb R, Ratanatharathorn V (2000) Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 96:2062–2068

    CAS  PubMed  Google Scholar 

  95. Fung J, Abu-Elmagd K, Jain A, Gordon R, Tzakis A, Todo S, Takaya S, Alessiani M, Demetris A, Bronster O (1991) A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. Transplant Proc 23:2977–2983

    CAS  PubMed  Google Scholar 

  96. Morice WG, Brunn GJ, Wiederrecht G, Siekierka JJ, Abraham RT (1993) Rapamycin-induced inhibition of p34cdc2 kinase activation is associated with G1/S-phase growth arrest in T lymphocytes. J Biol Chem 268:3734–3738

    CAS  PubMed  Google Scholar 

  97. Benito AI, Furlong T, Martin PJ, Anasetti C, Appelbaum FR, Doney K, Nash RA, Papayannopoulou T, Storb R, Sullivan KM, Witherspoon R, Deeg HJ (2001) Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation 72:1924–1929

    Article  CAS  PubMed  Google Scholar 

  98. Chen BJ, Morris RE, Chao NJ (2000) Graft-versus-host disease prevention by rapamycin: cellular mechanisms. Biol Blood Marrow Transplant 6:529–536

    CAS  PubMed  Google Scholar 

  99. Antin JH, Kim HT, Cutler C, Ho VT, Lee SJ, Miklos DB, Hochberg EP, Wu CJ, Alyea EP, Soiffer RJ (2003) Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood 102:1601–1605

    Article  CAS  PubMed  Google Scholar 

  100. Franklin TJ, Cook JM (1969) The inhibition of nucleic acid synthesis by mycophenolic acid. Biochem J 113:515–521

    CAS  PubMed  Google Scholar 

  101. Storb R, Yu C, Wagner JL, Deeg HJ, Nash RA, Kiem HP, Leisenring W, Shulman H (1997) Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 89:3048–3054

    CAS  PubMed  Google Scholar 

  102. Storb R, Yu C, Zaucha JM, Deeg HJ, Georges G, Kiem HP, Nash RA, McSweeney PA, Wagner JL (1999) Stable mixed hematopoietic chimerism in dogs given donor antigen, CTLA4Ig, and 100 cGy total body irradiation before and pharmacologic immunosuppression after marrow transplant. Blood 94:2523–2529

    CAS  PubMed  Google Scholar 

  103. Raefsky EL, Gascon P, Gratwohl A, Speck B, Young NS (1986) Biological and immunological characterization of ATG and ALG. Blood 68:712–719

    CAS  PubMed  Google Scholar 

  104. Weiden PL, Doney K, Storb R, Thomas ED (1979) Antihuman thymocyte globulin for prophylaxis of graft-versus-host disease. A randomized trial in patients with leukemia treated with HLA-identical sibling marrow grafts. Transplantation 27:227–233

    CAS  PubMed  Google Scholar 

  105. Doney KC, Weiden PL, Storb R, Thomas ED (1981) Failure of early administration of antithymocyte globulin to lessen graft-versus-host disease in human allogeneic marrow transplant recipients. Transplantation 31:141–148

    CAS  PubMed  Google Scholar 

  106. Bacigalupo A, Lamparelli T, Bruzzi P, Guidi S (2001) Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 98:2942–2949

    Article  CAS  PubMed  Google Scholar 

  107. Finke J, Bertz H, Schmoor C, Veelken H, Behringer D, Wasch R, Kunzmann R, Heidecker L, Lang H, Meyer-Konig U, Mertelsmann R (2000) Allogeneic bone marrow transplantation from unrelated donors using in vivo anti-T-cell globulin. Br J Haematol 111:303–313

    Article  CAS  PubMed  Google Scholar 

  108. Finke J, Schmoor C, Lang H, Potthoff K, Bertz H (2003) Matched and mismatched allogeneic stem-cell transplantation from unrelated donors using combined graft-versus-host disease prophylaxis including rabbit anti-T lymphocyte globulin. J Clin Oncol 21:506–513

    Article  PubMed  Google Scholar 

  109. Zander AR, Kroger N, Schleuning M, Finke J, Zabelina T, Beelen D, Schwerdtfeger R, Baurmann H, Bornhauser M, Ehninger G, Fauser AA, Kiehl M, Trenschel R, Ottinger HD, Bertz H, Berger J, Kolb HJ, Schaefer UW (2003) ATG as part of the conditioning regimen reduces transplant-related mortality (TRM) and improves overall survival after unrelated stem cell transplantation in patients with chronic myelogenous leukemia (CML). Bone Marrow Transplant 32:355–361

    Article  CAS  PubMed  Google Scholar 

  110. Bhatia S, Ramsay NK, Steinbuch M, Dusenbery KE, Shapiro RS, Weisdorf DJ, Robison LL, Miller JS, Neglia JP (1996) Malignant neoplasms following bone marrow transplantation. Blood 87:3633–3639

    CAS  PubMed  Google Scholar 

  111. Gratama JW, Jansen J, Lipovich RA, Tanke HJ, Goldstein G, Zwaan FE (1984) Treatment of acute graft-versus-host disease with monoclonal antibody OKT3. Clinical results and effect on circulating T lymphocytes. Transplantation 38:469–474

    CAS  PubMed  Google Scholar 

  112. Gleixner B, Kolb HJ, Holler E, Liesenfeld S, Riedner C, Hiller E, Seeber C, Kempeni J, Moller A, Knabe H, et al. (1991) Treatment of a GVHD with OKT3: clinical outcome and side-effects associated with release of TNF alpha. Bone Marrow Transplant 8:93–98

    CAS  PubMed  Google Scholar 

  113. Antin JH, Weinstein HJ, Guinan EC, McCarthy P, Bierer BE, Gilliland DG, Parsons SK, Ballen KK, Rimm IJ, Falzarano G, et al. (1994) Recombinant human interleukin-1 receptor antagonist in treatment of steroid-resistant graft-versus-host disease. Blood 84:1342–1348

    CAS  PubMed  Google Scholar 

  114. Antin JH, Weisdorf D, Neuberg D, Nicklow R, Clouthier S, Lee SJ, Alyea E, McGarigle C, Blazar BR, Sonis S, Soiffer RJ, Ferrara JL (2002) Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation. Blood 100:3479–3482

    Article  CAS  PubMed  Google Scholar 

  115. D’Sa S, Peggs K, Pizzey A, Verfuerth S, Thuraisundaram D, Watts M, White H, Hale G, Waldmann H, Goldstone A, Mackinnon S, Yong K (2003) T- and B-cell immune reconstitution and clinical outcome in patients with multiple myeloma receiving T-cell-depleted, reduced-intensity allogeneic stem cell transplantation with an alemtuzumab-containing conditioning regimen followed by escalated donor lymphocyte infusions. Br J Haematol 123:309–322

    Article  CAS  PubMed  Google Scholar 

  116. Chakrabarti S, MacDonald D, Hale G, Holder K, Turner V, Czarnecka H, Thompson J, Fegan C, Waldmann H, Milligan DW (2003) T-cell depletion with Campath-1H “in the bag” for matched related allogeneic peripheral blood stem cell transplantation is associated with reduced graft-versus-host disease, rapid immune constitution and improved survival. Br J Haematol 121:109–118

    PubMed  Google Scholar 

  117. Morris EC, Rebello P, Thomson KJ, Peggs KS, Kyriakou C, Goldstone AH, Mackinnon S, Hale G (2003) Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications. Blood 102:404–406

    Article  CAS  PubMed  Google Scholar 

  118. Chena HR, Jia SQ, Wanga HX, Yana HM, Liua LZJ, Xuea M, Xun CQ (2003) Humanized anti-CD25 monoclonal antibody for prophylaxis of graft-vs-host disease (GVHD) in haploidentical bone marrow transplantation without ex vivo T-cell depletion. Exp Hematol 31:1019–1025

    Article  PubMed  Google Scholar 

  119. Anasetti C, Hansen JA, Waldmann TA, Appelbaum FR, Davis J, Deeg HJ, Doney K, Martin PJ, Nash R, Storb R, et al. (1994) Treatment of acute graft-vs-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. Blood 84:1320–1327

    CAS  PubMed  Google Scholar 

  120. Cahn JY, Bordigoni P, Tiberghien P, Milpied N, Brion A, Widjenes J, Lioure B, Michel G, Burdach S, Kolb HJ, et al. (1995) Treatment of acute graft-versus-host disease with methylprednisolone and cyclosporine with or without an anti-interleukin-2 receptor monoclonal antibody. A multicenter phase III study. Transplantation 60:939–942

    CAS  PubMed  Google Scholar 

  121. Przepiorka D, Kernan NA, Ippoliti C, Papadopoulos EB, Giralt S, Khouri I, Lu JG, Gajewski J, Durett A, Cleary K, Champlin R, Andersson BS, Light S (2000) Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-vs-host disease. Blood 95:83–89

    CAS  PubMed  Google Scholar 

  122. Srinivasan R, Chakrabarti S, Walsh T, Igarashi T, Takahashi Y, Kleiner D, Donohue T, Shalabi R, Carvallo C, Barrett AJ, Geller N, Childs R (2004) Improved survival in steroid-refractory acute graft versus host disease after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis. Br J Haematol 124:777–786

    CAS  PubMed  Google Scholar 

  123. Pfister K, Wittig BM, Jungling B, Ecker KW, Barth S, Huhn M, Sasse S, Engert A, Mueller-Molaian I, Diehl V, Zeitz M, Stallmach A (2002) The in vitro inflammatory effects of recombinant anti-CD25 immunotoxin on lamina propria T cells of patients with inflammatory bowel disease are not sufficient to cure experimental colitis in mice. Int J Colorectal Dis 17:77–84

    Article  CAS  PubMed  Google Scholar 

  124. Barth S, Huhn M, Matthey B, Schnell R, Tawadros S, Schinkothe T, Lorenzen J, Diehl V, Engert A (2000) Recombinant anti-CD25 immunotoxin RFT5(SCFV)-ETA′ demonstrates successful elimination of disseminated human Hodgkin lymphoma in SCID mice. Int J Cancer 86:718–724

    Article  CAS  PubMed  Google Scholar 

  125. Kreitman RJ (2003) Recombinant toxins for the treatment of cancer. Curr Opin Mol Ther 5:44–51

    CAS  PubMed  Google Scholar 

  126. Korngold R, Marini JC, de Baca ME, Murphy GF, Giles-Komar J (2003) Role of tumor necrosis factor-alpha in graft-versus-host disease and graft-versus-leukemia responses. Biol Blood Marrow Transplant 9:292–303

    Article  CAS  PubMed  Google Scholar 

  127. Holler E, Kolb HJ, Mittermuller J, Kaul M, Ledderose G, Duell T, Seeber B, Schleuning M, Hintermeier-Knabe R, Ertl B, et al. (1995) Modulation of acute graft-versus-host-disease after allogeneic bone marrow transplantation by tumor necrosis factor alpha (TNF alpha) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF alpha (MAK 195F). Blood 86:890–899

    CAS  PubMed  Google Scholar 

  128. Jacobsohn DA (2002) Novel therapeutics for the treatment of graft-versus-host disease. Expert Opin Investig Drugs 11:1271–1280

    CAS  PubMed  Google Scholar 

  129. O’Reilly RJ, Collins N, Dinsmore R, Kernan N, Siena S, Brochstein J, Kirkpatrick D, Flomenberg N, Shank B, Dupont B (1985) Transplantation of HLA-mismatched marrow depleted of T-cells by lectin agglutination and E-rosette depletion. Tokai J Exp Clin Med 10:99–107

    CAS  PubMed  Google Scholar 

  130. Hessner MJ, Endean DJ, Casper JT, Horowitz MM, Keever-Taylor CA, Roth M, Flomenberg N, Drobyski WR (1995) Use of unrelated marrow grafts compensates for reduced graft-versus-leukemia reactivity after T-cell-depleted allogeneic marrow transplantation for chronic myelogenous leukemia. Blood 86:3987–3996

    CAS  PubMed  Google Scholar 

  131. Henslee-Downey PJ, Abhyankar SH, Parrish RS, Pati AR, Godder KT, Neglia WJ, Goon-Johnson KS, Geier SS, Lee CG, Gee AP (1997) Use of partially mismatched related donors extends access to allogeneic marrow transplant. Blood 89:3864–3872

    CAS  PubMed  Google Scholar 

  132. Champlin RE, Passweg JR, Zhang MJ, Rowlings PA, Pelz CJ, Atkinson KA, Barrett AJ, Cahn JY, Drobyski WR, Gale RP, Goldman JM, Gratwohl A, Gordon-Smith EC, Henslee-Downey PJ, Herzig RH, Klein JP, Marmont AM, O’Reilly RJ, Ringden O, Slavin S, Sobocinski KA, Speck B, Weiner RS, Horowitz MM (2000) T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities. Blood 95:3996–4003

    CAS  PubMed  Google Scholar 

  133. Aversa F, Tabilio A, Terenzi A, Velardi A, Falzetti F, Giannoni C, Iacucci R, Zei T, Martelli MP, Gambelunghe C, et al. (1994) Successful engraftment of T-cell-depleted haploidentical “three-loci” incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 84:3948–3955

    CAS  PubMed  Google Scholar 

  134. Rachamim N, Gan J, Segall H, Krauthgamer R, Marcus H, Berrebi A, Martelli M, Reisner Y (1998) Tolerance induction by “megadose” hematopoietic transplants: donor-type human CD34 stem cells induce potent specific reduction of host anti-donor cytotoxic T lymphocyte precursors in mixed lymphocyte culture. Transplantation 65:1386–1393

    CAS  PubMed  Google Scholar 

  135. Reinherz EL, Geha R, Rappeport JM, Wilson M, Penta AC, Hussey RE, Fitzgerald KA, Daley JF, Levine H, Rosen FS, Schlossman SF (1982) Reconstitution after transplantation with T-lymphocyte-depleted HLA haplotype-mismatched bone marrow for severe combined immune deficiency. Proc Natl Acad Sci U S A 79:6047–6051

    CAS  PubMed  Google Scholar 

  136. Soiffer RJ, Murray C, Cochran K, Cameron C, Wang E, Schow PW, Daley JF, Ritz J (1992) Clinical and immunological effects of prolonged infusions of low dose recombinant interleukin-2 after autologous and T-cell depleted allogeneic bone marrow transplantation. Blood 79:517–521

    CAS  PubMed  Google Scholar 

  137. Gandy KL, Domen J, Aguila H, Weissman IL (1999) CD8+TCR+ and CD8+TCR cells in whole bone marrow facilitate the engraftment of hematopoietic stem cells across allogeneic barriers. Immunity 11:579–590

    Article  CAS  PubMed  Google Scholar 

  138. Schuchert MJ, Wright RD, Colson YL (2000) Characterization of a newly discovered T-cell receptor [beta]-chain heterodimer expressed on CD8-positive bone marrow subpopulation that promotes allogeneic stem cell engraftment. Nat Med 6:904–909

    Article  CAS  PubMed  Google Scholar 

  139. Lan F, Zeng D, Huie P, Higgins JP, Strober S (2001) Allogeneic bone marrow cells that facilitate complete chimerism and eliminate tumor cells express both CD8 and T-cell antigen receptor-[alpha][beta]. Blood 97:3458–3465

    CAS  PubMed  Google Scholar 

  140. Alyea EP, Weller E, Fisher DC, Freedman AS, Gribben JG, Lee S, Schlossman RL, Stone RM, Friedberg J, DeAngelo D, Liney D, Windawi S, Ng A, Mauch P, Antin JH, Soiffer RJ (2002) Comparable outcome with T-cell-depleted unrelated-donor versus related-donor allogeneic bone marrow transplantation. Biol Blood Marrow Transplant 8:601–607

    Article  PubMed  Google Scholar 

  141. Koh MB, Prentice HG, Corbo M, Morgan M, Cotter FE, Lowdell MW (2002) Alloantigen-specific T cell depletion in a major histocompatibility mismatched murine model provides effective graft-versus-host disease prophylaxis in the presence of lymphoid engraftment. Br J Haematol 118:108–116

    Article  CAS  PubMed  Google Scholar 

  142. Rencher SD, Houston JA, Lockey TD, Hurwitz JL (1996) Eliminating graft-versus-host potential from T cell immunotherapeutic populations. Bone Marrow Transplant 18:415–420

    CAS  PubMed  Google Scholar 

  143. Gribben JG, Guinan EC, Boussiotis VA, Ke XY, Linsley L, Sieff C, Gray GS, Freeman GJ, Nadler LM (1996) Complete blockade of B7 family-mediated costimulation is necessary to induce human alloantigen-specific anergy: a method to ameliorate graft-versus-host disease and extend the donor pool. Blood 87:4887–4893

    CAS  PubMed  Google Scholar 

  144. Blazar BR, Taylor PA Noelle RJ, Vallera DA (1998) CD4(+) T cells tolerized ex vivo to host alloantigen by anti-CD40 ligand (CD40L:CD154) antibody lose their graft-versus-host disease lethality capacity but retain nominal antigen responses. J Clin Invest 102:473–482

    CAS  PubMed  Google Scholar 

  145. Cavazzana-Calvo M, Fromont C, Le Deist F, Lusardi M, Coulombel L, Derocq JM, Gerota I, Griscelli C, Fischer A (1990) Specific elimination of alloreactive T cells by an anti-interleukin-2 receptor B chain specific immunotoxin. Transplantation 50:1–7

    CAS  PubMed  Google Scholar 

  146. Hartwig U, Robbers M, Wickenhauser C, Huber C (2002) Murine acute graft-versus-host disease can be prevented by depletion of alloreactive T lymphocytes using activation-induced cell death. Blood 100:375–382

    Article  PubMed  Google Scholar 

  147. Chen BJ, Chui X, Cjao NJ (2002) Prevention of graft-versus-host disease while preserving graft-versus-leukemia effect after selective depletion of host-reactive T cells by photodynamic cell purging process. Blood 99:3083–3088

    Article  CAS  PubMed  Google Scholar 

  148. Guimond M, Balassy A, Barrette M, Brochu S, Perreault C, Roy DC (2002) P-glycoprotein targeting: a unique strategy to selectively eliminate immunoreactive T cells. Blood 99:3041–3049

    Article  CAS  PubMed  Google Scholar 

  149. Barrett AJ, Malkovska V (1996) Graft-versus-leukaemia: understanding and using the alloimmune response to treat haematological malignancies. Br J Haematol 93:754–761

    Article  CAS  PubMed  Google Scholar 

  150. Michalek J, Collins RH, Durrani HP, Vaclavkova P, Ruff LE, Douek DC, Vitetta ES (2003) Definitive separation of graft-versus-leukemia and graft-versus-host specific CD4+ T cells by virtue of their receptor beta loci sequences. Proc Natl Acad Sci U S A 100:1180–1184

    Article  CAS  PubMed  Google Scholar 

  151. Cavazzana-Calvo M, Stephan JL, Sarnacki S, Chevret S, Fromont C, de Coene C, Le Deist F, Guy-Grand D, Fischer A (1994) Attenuation of graft-versus-host disease and graft rejection by ex vivo immunotoxin elimination of alloreactive T cells in an H-2 haplotype disparate mouse combination. Blood 83:288–298

    CAS  PubMed  Google Scholar 

  152. Guinan EC, Boussiotis VA, Neuberg D, Brennan LL, Hirano N, Nadler LM, Gribben JG (1999) Transplantation of anergic histoincompatible bone marrow allografts. N Engl J Med 340:1704–1714

    CAS  PubMed  Google Scholar 

  153. Solomon SR, Tran T, Carter CS, Donnelly S, Hensel N, Schindler J, Bahceci E, Ghetie V, Michalek J, Mavroudis D, Read EJ, Vitetta ES, Barrett AJ (2002) Optimized clinical scale culture conditions for ex vivo selective depletion of host-reactive lymphocytes: a strategy for GVHD prophylaxis in allogeneic peripheral blood stem cell transplantation. Cytotherapy 4:395–406

    Article  CAS  PubMed  Google Scholar 

  154. Andre-Schmutz I, Le Deist F, Hacein-Bey-Abina S, Vitetta E, Schindler J, Chedeville G, Vilmer E, Fischer A, Cavazzana-Calvo M (2002) Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a phase I/II study. Lancet 360:130–137

    Article  PubMed  Google Scholar 

  155. Fowler DH, Kurasawa K, Smith R, Eckhaus MA, Gress RE (1994) Donor CD4-enriched cells of Th2 cytokine phenotype regulate graft-versus-host disease without impairing allogeneic engraftment in sublethally irradiated mice. Blood 84:3540–3549

    CAS  PubMed  Google Scholar 

  156. Fowler DH, Breglio J, Nagel G, Hirose C, Gress RE (1996) Allospecific CD4+, Th1/Th2 and CD8+,Tc1/Tc2 populations inmurine GVL: type I cells generate GVL and type II cells abrogate GVL. Biol Blood Marrow Transplant 2:118–125

    CAS  PubMed  Google Scholar 

  157. Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, Ruggieri L, Ponzoni M, Rossini S, Mavilio F, Traversari C, Bordignon C (1997) HSV Tk gene transfer into donor lymphocytes for control of allogeneic graft-versus leukemia. Science 27:1719–1724

    Article  Google Scholar 

  158. Tiberghien P (2001) Use of suicide gene expressing donor T cells to control alloreactivity after hematopoietic stem cell transplantation. J Intern Med 249:369–377

    Article  CAS  PubMed  Google Scholar 

  159. Tiberghien P, Reynolds CW, Keller J, Spence S, Deschaseaux M, Certoux JM, Contassot E, Murphy WJ, Lyons R, Chiang Y, et al. (1994) Ganciclovir treatment of herpes simplex thymidine kinase-transduced primary T lymphocytes: an approach for specific in vivo donor T-cell depletion after bone marrow transplantation? Blood 84:1333–1341

    CAS  PubMed  Google Scholar 

  160. Springer CJ, Niculescu-Duvaz I (2000) Prodrug-activating systems in suicide gene therapy. J Clin Invest 105:1161–1167

    CAS  PubMed  Google Scholar 

  161. Champlin R, Bensinger W, Henslee-Downey J, et al. (1999) Phase I/II study of thymidine kinase-transduced donor lymphocyte infusions in patients with hematological malignancies. Blood 94 [Suppl 1]:324a

    Google Scholar 

  162. Link CJ Jr, Traynor A, Seregina T, Burt RK (1998) Adoptive immunotherapy for leukemia: donor lymphocytes transduced with the herpes simplex thymidine kinase gene for remission induction. Hum Gene Ther 9:115–134

    CAS  PubMed  Google Scholar 

  163. Link CJ, Drobyski WR, Traynor AE, et al. (1999) Adoptive immunotherapy for leukemia: donor lymphocytes transduced with the herpes simplex thymidine kinase gene. Blood 94 [Suppl 1]:366a

    Google Scholar 

  164. Tiberghien P, Ferrand C, Lioure B, Milpied N, Angonin R, Deconinck E, Certoux JM, Robinet E, Saas P, Petracca B, Juttner C, Reynolds CW, Longo DL, Herve P, Cahn JY (2001) Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. Blood 97:63–72

    Article  CAS  PubMed  Google Scholar 

  165. Koehne G, Gallardo HF, Sadelain M, O’Reilly RJ (2000) Rapid selection of antigen-specific T lymphocytes by retroviral transduction. Blood 96:109–117

    CAS  PubMed  Google Scholar 

  166. Marktel S, Magnani Z, Ciceri F, Cazzaniga S, Riddell SR, Traversari C, Bordignon C, Bonini C (2003) Immunologic potential of donor lymphocytes expressing a suicide gene for early immune reconstitution after hematopoietic T-cell-depleted stem cell transplantation. Blood 101:1290–1298

    Article  CAS  PubMed  Google Scholar 

  167. Shevach EM (2001) Certified professionals: CD4(+)CD25(+) suppressor T cells. J Exp Med 193:41–46

    Article  Google Scholar 

  168. Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S (2002) Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 196:389–399

    Article  CAS  PubMed  Google Scholar 

  169. Stephens LA, Mottet C, Mason D, Powrie F (2001) Human CD4(+)CD25(+) thymocytes and peripheral T cells have immune suppressive activity in vitro. Eur J Immunol 31:1247–1254

    Article  CAS  PubMed  Google Scholar 

  170. Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA (2001) CD4+CD25 high regulatory cells in human peripheral blood. J Immunol 167:1245–1253

    CAS  PubMed  Google Scholar 

  171. Hori S, Nomura T, Sakaguchi S (2003) Control of regulatory T cell development by the transcription factor Foxp3. Science 299:1057–1061

    Article  CAS  PubMed  Google Scholar 

  172. Walker MR, Kasprowicz DJ, Gersuk VH, Benard A, Van Landeghen M, Buckner JH, Ziegler SF (2003) Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25− T cells. J Clin Invest 112:1437–1443

    Article  CAS  PubMed  Google Scholar 

  173. Annacker O, Pimenta-Araujo R, Burlen-Defranoux O, Barbosa TC, Cumano A, Bandeira A (2001) CD25+CD4+ T cells regulate the expansion of peripheral CD4 T cells through the production of IL-10. J Immunol 166:3008–3018

    CAS  PubMed  Google Scholar 

  174. Murakami M, Sakamoto A, Bender J, Kappler J, Marrack P (2002) CD25+CD4+ T cells contribute to the control of memory CD8+ T cells. Proc Natl Acad Sci U S A 99:8832–8837

    Article  CAS  PubMed  Google Scholar 

  175. Kingsley CI, Karim M, Bushell AR, Wood KJ (2002) CD25(+)CD4(+) regulatory T cells prevent graft rejection: CTLA-4- and IL-10-dependent immunoregulation of alloresponses. J Immunol 168:1080–1086

    CAS  PubMed  Google Scholar 

  176. Field EH, Matesic D, Rigby S, Fehr T, Rouse T, Gao Q (2001) CD4+CD25+ regulatory cells in acquired MHC tolerance. Immunol Rev 182:99–112

    Article  CAS  PubMed  Google Scholar 

  177. Taylor PA, Lees CJ, Blazar BR (2002) The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood 99:3493–3499

    Article  CAS  PubMed  Google Scholar 

  178. Edinger M, Hoffmann P, Ermann J, Drago K, Fathman CG, Strober S, Negrin RS (2003) CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 9:1144–1150

    Article  CAS  PubMed  Google Scholar 

  179. Dieckmann D, Plottner H, Berchtold S, Berger T, Schuler G (2001) Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J Exp Med 193:1303–1311

    Article  CAS  PubMed  Google Scholar 

  180. Levings M, Sangregorio R, Roncarolo M (2001) Human CD25+CD4+T regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med 193:1295–1301

    Article  CAS  PubMed  Google Scholar 

  181. Hoffmann P, Eder R, Kunz-Schughart LA, Andreesen R, Edinger M (2004) Large scale in vitro expansion of polyclonal human CD4+CD25high regulatory T cells. Blood [Epub ahead of print]

  182. Forster R, Schubel A, Breitfeld D, Kremmer E, Renner-Muller I, Wolf E, Lipp M (1999) CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 99:23–33

    CAS  PubMed  Google Scholar 

  183. Szanya V, Ermann J, Taylor C, Holness C, Fathman CG (2002) The subpopulation of CD4+CD25+ splenocytes that delays adoptive transfer of diabetes expresses l-selectin and high levels of CCR7. J Immunol 169:2461–2466

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology and Oncology, Albert Ludwigs University Medical Center Freiburg, Hugstetterstr. 55, 79106, Freiburg, Germany

    Robert Zeiser, Reinhard Marks, Hartmut Bertz & Jürgen Finke

Authors
  1. Robert Zeiser
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Reinhard Marks
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hartmut Bertz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jürgen Finke
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert Zeiser.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zeiser, R., Marks, R., Bertz, H. et al. Immunopathogenesis of acute graft-versus-host disease: implications for novel preventive and therapeutic strategies. Ann Hematol 83, 551–565 (2004). https://doi.org/10.1007/s00277-004-0890-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-004-0890-7

Keywords

Search

Navigation